Neuroimaging and Siemens Healthineers’ Push to Build a Neuro Platform

Siemens Healthineers sits among the largest companies in medtech. With approximately $25 billion in revenue in 2025, the company operates at a scale comparable to some of the industry’s biggest names and continues to invest heavily in markets where it sees long-term growth potential.

A series of partnership announcements over the past year offers a window into where Siemens Healthineers appears to be investing for the future. Across robotics, AI, diagnostics software, and health system infrastructure, Siemens Healthineers has assembled a network of relationships that increasingly points toward one destination: neuro. Viewed individually, each agreement serves a specific purpose. Taken together, they suggest a broader strategy centered on neuroimaging, precision therapy, and integrated clinical workflows.

A Company Becoming More Focused

Siemens AG announced plans to deconsolidate its majority stake in Siemens Healthineers, a process that has been underway for some time. For Healthineers, that focus appears increasingly concentrated on businesses where it believes it holds the strongest competitive advantages.

Imaging and Precision Therapy are viewed as the highly synergistic core of the company, and both segments are also posting high single-digit growth. Diagnostics occupies a different position. By management’s own admission, the business has relatively few synergies with either segment. While no formal separation has been announced, the discussion reflects a broader trend toward portfolio simplification across medtech.

The company’s own reporting reinforces this view. Imaging and Precision Therapy remain central to the growth story, while Diagnostics continues to face challenges, particularly in China.

The Partnerships Behind the Strategy

During the last 12 months, Siemens Healthineers announced nine notable partnerships spanning multiple areas of healthcare technology.

Three stand out as especially relevant to its broader neuro ambitions.

The partnership with Stryker, announced in September 2025, focuses on neurovascular workflows. The collaboration combines Siemens Healthineers’ imaging capabilities with Stryker’s therapeutic devices to support stroke and neurovascular interventions.

In May 2026, Siemens Healthineers partnered with Cercare Medical to integrate Cercare’s Neurosuite platform into syngo DynaCT. The combination enables automated cone-beam CT perfusion imaging within the angiography suite, with the goal of reducing the time between stroke diagnosis and treatment.

Another May 2026 announcement connected LSI Alumni company AiM Medical Robotics’ MRI-compatible robotic neurosurgery platform with Siemens Healthineers’ MAGNETOM MRI scanners. The collaboration enables real-time in-bore guidance during brain biopsies and neurostimulation procedures.

Building a Neuro Ecosystem

Additional agreements further strengthen the company’s position.

Methinks AI joined the ecosystem in October 2025, bringing AI-driven acute stroke triage capabilities. In February 2026, Siemens Healthineers and Mayo Clinic announced a collaboration focused on clinical digital twins and AI-enabled MRI/PET protocols for neurodegenerative disease and oncology applications.

The company has also signed health system partnerships with Northwestern Medicine, Onvida Health, and Hawaii Pacific Health. While less visible than robotics or AI announcements, these relationships help reinforce imaging infrastructure adoption across large provider networks.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/neuroimaging-and-siemens-healthineers-push-to-build-a-neuro-platform

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

Microbot Medical and the Endovascular Robotics Opportunity Taking Shape

In November, Microbot Medical reached a meaningful milestone in the evolution of endovascular robotics, announcing that Emory University Hospital in Atlanta has become the first hospital worldwide to use the company’s LIBERTY system for patient care. Microbot is currently operating under a limited commercial release following FDA clearance, with a broader market launch planned for April 2026 at the Society of Interventional Radiology conference. While still early, the move signals growing confidence that robotic assistance inside the vasculature is beginning to transition from concept to clinical reality. To understand why this matters, it helps to step back and examine the numbers behind the endovascular robotics market and how Microbot’s approach fits into a rapidly evolving competitive landscape. Defining the Endovascular Procedure Landscape Endovascular procedures encompass any intervention performed from within a blood vessel. In practical terms, this includes coronary, periphe...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more